Comprehensive Monitoring of Men With Prostate Cancer Cared for by "Active Surveillance

You may be eligible if

• 1. Patients will have histologic diagnosis of adenocarcinoma of the prostate within 24 months of study entry.
• 2. Patient must meet at least one of the following clinical indications for AS: National Comprehensive Cancer Network (NCCN) very low risk or low risk prostate cancer meeting consensus guidelines for AS; NCCN intermediate-risk prostate cancer requesting AS (per patient and clinician shared decision making); or have severe medical comorbidities (defined as CCI estimated 10-year survival \< 50% and agreed by treating clinician) with high- or very high-risk localized prostate cancer.
• 3. Patients must agree to comply with the surveillance schedule.
• 4. Patients must be over 18 years of age
• 5. Written informed consent
• 6. Patients must be fluent in the English language to participate in the patient report outcome and symptoms monitoring portion of the trial.
• 2. Prior radiation therapy for treatment of the primary tumor.
• 3. Planned concomitant hormonal therapy, chemotherapy, or radiation therapy while on protocol